Recombinant HIV-1 Envelope Protein for Vaccine Use
In pursuit of an effective vaccine to end the global HIV-1/AIDS pandemic, researchers at the Vaccine Research Center (“VRC”) continue to study the structure of HIV-1. Recently, these researchers have determined the three-dimensional structure of the HIV-1 Envelope trimeric ectodomain (“Env”), comprised of three gp120 and three gp41 subunits, in its prefusion, mature, closed conformation.
The researchers hypothesize that immunization with the prefusion, closed HIV-1 Env protein will elicit a neutralizing immune response. The VRC researchers engineered a portion of the HIV-1 Env trimer to stabilize it in this closed conformation for use as an immunogen.
This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.
Potential Commercial Applications: | Competitive Advantages: |
|
|
Inventors:
Peter Kwong (NIAID) ➽ more inventions...
Marie Pancera (NIAID) ➽ more inventions...
Tongqing Zhou (NIAID) ➽ more inventions...
Ivelin Georgiev (NIAID) ➽ more inventions...
Michael Joyce (NIAID) ➽ more inventions...
Priyamvada Acharya (NIAID) ➽ more inventions...
Jason Gorman (NIAID) ➽ more inventions...
Yongping Yang (NIAID) ➽ more inventions...
Aliaksandr Druz (NIAID) ➽ more inventions...
Guillaume Stewart-Jones (NIAID) ➽ more inventions...
Rita Chen (NIAID) ➽ more inventions...
Gwo-Yu Chuang (NIAID) ➽ more inventions...
Ulrich Baxa (NIAID) ➽ more inventions...
John Mascola (NIAID) ➽ more inventions...
Rebecca Lynch (NIAID) ➽ more inventions...
Baoshan Zhang (NIAID) ➽ more inventions...
Cheng Cheng (NIAID) ➽ more inventions...
Intellectual Property:
U.S. Pat: 10,400,015 issued 2019-09-03
US Application No. 62/136,480
PCT Application No. PCT/US2015/048729
US Application No. 15/508,885
US Application No. 16/557,894
Publications:
Pancera M, et al. PMID 25296255
Collaboration Opportunity:
The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize HIV-1 immunogens for treating or preventing HIV-1 infection. For collaboration opportunities, please contact Dr. Barry Buchbinder, 240-627-3674; barry.buchbinder@nih.gov.
Licensing Contact:
Barry Buchbinder, Ph.D.
Email: BBuchbinder@niaid.nih.gov
Phone: 301-496-2644
OTT Reference No: E-178-2014-0
Updated: Oct 18, 2018